BioCentury | Jun 27, 2020
Translation in Brief

Regeneron enhances checkpoint therapy with CD28 bispecifics; plus NIH funds Alzheimer’s brain mapping, Genentech and more

Regeneron combines CD28 bispecifics with PD-1 mAb  In its latest paper covering anti-CD28 bispecific antibodies, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) showed in Science Translational Medicine that the bispecifics could boost anti-PD-1 efficacy. Bispecifics against CD28 and...
BioCentury | Jun 15, 2020
Product Development

NCATS seeks to create hub for COVID-19 data; Regeneron reports preclinical data backing antiviral mAb cocktail

NIH’s NCATS has launched a collaborative aimed at facilitating data sharing among COVID-19 countermeasure developers. The National Center for Advancing Translational Sciences (NCATS) said the National COVID Cohort Collaborative (NC3) seeks to create a centralized...
BioCentury | Apr 24, 2020
Product Development

April 23 Quick Takes: Hansoh, NiKang partner for antiviral; plus Jakafi, Avastin, EpimAb-QIMR, ProThera-Takeda

Hansoh gains China rights to NiKang antiviral  Hansoh Pharmaceutical Group Co. Ltd. (HKEX:03692) gained rights to develop and commercialize NKT-1992 from NiKang Therapeutics Inc. for viral diseases in Greater China. NiKang is eligible to receive...
BioCentury | Apr 15, 2020
Product Development

Why Lilly chose NIH’s COVID-19 master protocol for Olumiant

Eli Lilly's decision to evaluate rheumatoid arthritis drug Olumiant baricitinib via NIH's COVID-19 master protocol highlights the model’s value for companies during the pandemic. It also raises a series of questions about how companies will...
BioCentury | Apr 3, 2020
Product Development

COVID-19 roundup: Amgen taps Adaptive as its antibody therapeutic partner; plus Alnylam-Vir’s siRNA targets, Ansun’s data and more

Amgen entered the race to develop an antibody-based COVID-19 therapy Thursday, partnering with Adaptive Biotechnologies to screen for neutralizing mAbs. The day also saw Alnylam and Vir name the first targets from their siRNA partnership...
BioCentury | Mar 31, 2020

Lilly gains rights to Sitryx’s two most advanced immunometabolic programs in four-target deal

For its first pharma partnership, U.K.-based Sitryx is granting Lilly rights to its two most advanced immunometabolism programs in exchange for upfront cash and an equity investment totaling $60 million -- twice the amount of...
BioCentury | Mar 7, 2020
Emerging Company Profile

Kira: depleting activated dendritic cells

First-in-class mAbs against activated dendritic cells from Australian newco Kira could block the inflammation and immune response associated with GvHD and autoimmune diseases without the risk of infection that accompanies broad immunosuppression. Founding CEO Dan...
BioCentury | Feb 5, 2020
Product Development

2019-nCoV drug discovery: HHS funds Regeneron mAbs and BenevolentAI deploys machine learning

Regeneron and BenevolentAI unveiled a deal and a platform, respectively, on Tuesday that could yield therapies against 2019-nCoV that go beyond anti-inflammatory drugs for other viral infections. The first nine clinical trials of medicines for...
BC Extra | Jan 29, 2020
Company News

Jan. 28 Company Quick Takes: Kite, Alkermes, Regeneron-Sanofi, Incyte, NantHealth-NantOmics, Sorrento, MicroCures, Paion-Mundipharma

Kite’s KTE-X19 under review in Europe   EMA has accepted an MAA for KTE-X19 from Kite, positioning the CAR T cell therapy from the Gilead Sciences Inc. (NASDAQ:GILD) unit to become the first CAR T...
BC Extra | Jan 10, 2020
Company News

Lilly bolsters atopic dermatitis arsenal via $1.1B Dermira deal, gaining Dupixent challenger

Via its $1.1 billion takeout of Dermira on Friday, Eli Lilly added to its late-stage pipeline an atopic dermatitis therapy that could challenge Dupixent. The price -- $18.75 per share -- is a premium of...
Items per page:
1 - 10 of 446